Mentions
Extended reach
Total likes
Video views
AI synopsis
The collective discussions reveal strong agreement on the drug's effectiveness, citing examples like 15% weight loss and referencing well-known studies (e.g., NEJM). The tone varies from optimistic recognition of its potential to cautious skepticism about side effects and long-term safety, reflecting both excitement and critical analysis.
Most discussions acknowledge the positive effects shown in the NEJM study, emphasizing weight loss of around 15%.
Many posts show high interest, citing detailed results and referencing studies, indicating engagement with the research.
Posts deeply analyze study data, side effects, and implications, reflecting high engagement; some question or critique aspects like muscle loss.
While users recognize the potential of semaglutide as a 'game-changer' for obesity treatment, some express skepticism about long-term effects and side effects, suggesting moderate impact.
New video: All about OZEMPIC (semaglutide), WEGOVY, MOUNJARO (tirzepatide) Are GLP-1 analogues safe? How do they work? What about side effects? Will they change the reality of public health? ft. @DrNadolsky https://t.co/GC16bHlYAx
1/ Ready for another #EBGI Tweetorial
✅ Semaglutide just approved for long-term weight loss by @US_FDA ✅ Average weight ⬇️ 15% (~34 pounds) in @NEJM study (by week 68) #EndoTwitter #weightloss https://t.co/Pn3ZAfeyaI https://t.co/g2OLXjlThw
✅ The dose used in the study was 2.4 mg of semaglutide once weekly. This is much higher than your 0.5 mg dose of Ozempic ✅ This means to achieve similar results, one has to buy 5 x 0.5 mg doses per week. For 68 weeks. Do the math. It ain’t cheap. https://t.co/x5oWtiYBZ2
The New England Journal of Medicineによれば、約2,000人の肥満成人を対象とした研究によって、糖尿病の治療であるセマグルチドの週1回の使用と減量によって15％程度の体重減少が認められたらしい。プラセボ群に比べても大きな差が得られたようで、新しい減量治療になるかも https://t.co/TMMBUvIy1w
@elonmusk We should consider that "losing weight" isn't always the best goal, and how we lose weight and what type of weight we lose may matter more. Here's a short video we did on this topic https://t.co/RyIVdhqG2n
Thanks to MUDWTR for sponsoring today's video. Get 15 Off with promo code ABBEYSHARP at httpsmudwtrcomABBEYSHARP. In this video, we explore whether Berberine, often called natures Ozempic, effectively lowers blood sugar…
This video compares the popular drug Ozempic with natural approaches acting on the same hormone, discussing their effects on appetite suppression and weight loss based on recent clinical trials and scientific research.
Type 2 diabetes and how intermittent fasting could help reverse the condition. A recent study observed the effects of fasting; after 3 months, nearly half of participants experienced reversal.
This video discusses the effects of Ozempic on the body after nine months, highlighting ongoing research and developments in weight loss medications, with insights from Abbey Sharp and updated medical information.
Weight loss drugs Ozempic, Wegovy, and Mounjaro are discussed, covering how they work and their safety. This video explains their roles as GLP1 mimetics for obesity and weight management.
This video explores the impact of Ozempic, a GLP-1 receptor agonist, on weight management. It discusses potential benefits and concerns regarding muscle loss, supported by recent research studies, to inform viewers…
This video examines the scientific evidence behind Berberine's claims for blood sugar control, cholesterol reduction, weight loss, cancer prevention, and anti-aging, comparing it to medications like metformin and…
This video discusses why focusing on body composition is more beneficial than weight loss alone. We explore how diets like ketogenic regimes can preserve muscle and promote fat loss, ultimately supporting long-term…
This video analyzes the impact of Ozempic, Wegovy, and Mounjaro on body composition. These GLP-1 receptor agonists have shown impressive efficacy in weight loss and altering body composition in individuals with type 2…
Peptides are gaining popularity with claims of fat loss, muscle growth, and healing. This video explains the most talked-about peptides, their research-backed benefits, risks, and the importance of FDA approval…
This episode examines the effects of GLP1 receptor agonists like Ozempic on body image and mental health, especially in individuals with normal weight seeking weight loss. Dr Yalda Safai discusses risks such as body…
Think twice before you wish for that quick fix. This video discusses the implications and considerations of Medicare covering Ozempic for weight loss, including potential risks and scientific insights from recent…
This video explores how Semaglutide, marketed as Ozempic or Wegovy, functions as a weight loss aid, examining its potential benefits and associated risks based on scientific research and recent FDA approvals.
What are the most common side effects of Ozempic semaglutide? This video reviews the top four reported in the STEP 1 trial, including nausea, diarrhea, constipation, and vomiting. Always consult a healthcare…
The STEP 1 trial evaluated weight loss and cardiometabolic health with semaglutide, revealing significant initial improvements that declined upon treatment discontinuation, emphasizing the need for ongoing management…
Discover the groundbreaking obesity treatment Terzepatide, a once-a-week injection transforming weight loss and type 2 diabetes management. This video explores the science behind GLP1 and GIP hormones, treatment…
This video provides a clear, study-based explanation of whether Ozempic, Wegovy, and Mounjaro weight loss pens cause rebound effects, why they happen, and how to avoid regaining lost weight. Designed for safe…
Ozempic was created to treat type 2 diabetes but is now popular on social media as a rapid weight loss solution. This video examines the drug's mechanism of action, potential side effects such as muscle loss, and the…
Explore promising hair loss treatments including RU58841 and related solutions, with discounts available. Learn about effective options for hair regeneration and hair care products that may help reverse balding.
Discover the truth behind new antiobesity drugs and the effects of weight cycling on diabetes risk. The meta-analysis reveals that repeated weight changes increase diabetes likelihood, especially in non-obese adults…
This video explores the role of GLP-1 receptor agonists in addressing obesity and other health issues. It reviews recent innovations, their effectiveness in treating obesity, heart disease, and neurodegenerative…
Wondering about GLP-1 medications like Wegovy or Ozempic? This video explains their impact on weight loss and muscle health. We'll discuss the benefits, side effects, and safety risks while providing nutrition tips to…
This video breaks down how semaglutide works inside the body. We explore its effects on hunger, blood sugar, and long-term weight loss, along with potential side effects and cardiovascular benefits supported by recent…
This video explains how Ozempic (semaglutide) works in weight management, blood sugar control, and obesity treatment, highlighting potential risks of misuse based on recent popularity and scientific research.
Explore the effectiveness of GLP-1 drugs like Ozempic, Wegovy, and Mounjaro for weight loss, with up to 20% reduction. Learn how they work, potential side effects, and long-term impact. Discover who benefits most and…
Beyond the Scales discusses the impact of ultraprocessed foods on weight control, featuring insights from medical students and a bariatric surgeon. The episode covers medications like semaglutide, orlistat, and GLP1…
The 2013 AHA/ACC and The Obesity Society guideline provides evidence-based recommendations for treating overweight and obesity in adults, emphasizing lifestyle changes, behavioral therapy, and, when necessary, medical…
This week in cardiology, we discuss coronary CTA, semaglutide for type 2 diabetes, and upcoming cardiology events. Semaglutide showed cardiovascular benefits in a recent study, but requires monitoring for retinopathy…
@dtklp1 @eryney_ok You are giving your impression of the space but it's not right. https://t.co/LREvRFXYkL
@BenBear73068268 @AlexJLeaf "Once-Weekly Semaglutide in Adults with Overweight or Obesity"
@Travislim88 In an ideal world, but many prescriptions are poorly regulated with no follow up. In the NEJM trial, lean body mass loss was 3.6% so certainly could be a cause of sarcopenia https://t.co/fUBxHkYnWz https://t.co/S6iaiXKw9P
1961 kişi ile yapılmış çalışmada örneklem grubuna haftada bir zayıflama iğnesi yapılmış. Sonuçta katılımcılar 1 yıl içinde vücut ağırlığının %15'ini kaybetmiş, 100 kg'dan 85 kg'ya düşmüş. Sağlıklı bir şekilde 2-3 ayda kolaylıkla verilebilir bir kilo. Doi:10.1056/NEJMoa2032183
@srikosuri Dosing is based on the doses that were used in the clinical trials for weight loss. These were based on dosing for diabetes treatment. Taper-up & taper-down were used for key clinical trials. https://t.co/Z96N0yERhS
RT @Logan5__: @IdoWolf1 מה לא מפתיע? שקוהורט רטרוספקטיבי מוטה אינהרנטית שנעשה על EHRs(ולא על מטופלים), מצא את מה שרצו למצוא מלכתחילה והלך ע…
@IdoWolf1 מה לא מפתיע? שקוהורט רטרוספקטיבי מוטה אינהרנטית שנעשה על EHRs(ולא על מטופלים), מצא את מה שרצו למצוא מלכתחילה והלך עד 2014, בעוד שהתרופה הרלוונטית לדיון( וויגובי) אושרה בכלל ב2021,על סמך מחקר שהראה עליית סיכון אבסולוטית של מעל 3% לSerious adverse eventsי? https://t.co/JeuEXJ2mY0 https://t.co/5s5bU7CoHX
-٧- https://t.co/yWKMxn0SxH #اوك_الطبية
RT @raphaels7: Taking 2.4 mg of semaglutide (Ozempic) for 68 weeks resulted in a reduction of food intake and a loss of nearly 17% of body…
Semaglutide Scientific Journal proving that its effective in adult age males & females by the New England Journal of Medicine: https://t.co/7jKBpuLtH1
Semaglutide Scientific Journal proving that its effective in adult age males & females by the New England Journal of Medicine: https://t.co/YgL7ItqYNP
Semaglutide Scientific Journal proving that its effective in adult age males & females by the New England Journal of Medicine: https://t.co/jkmmwRkm5F
Semaglutide Scientific Journal proving that its effective in adult age males & females by the New England Journal of Medicine: https://t.co/dlZO1URGnM
Semaglutide Scientific Journal proving that its effective in adult age males & females by the New England Journal of Medicine: https://t.co/sJBG1w6GIS
Semaglutide Scientific Journal proving that its effective in adult age males & females by the New England Journal of Medicine: https://t.co/LZglUP4CBC
@RichardHanania It’s about 10-15% of people who are “non-responders” to ozempic, so yea Ozempic didn’t kill that argument but rather supported it. Science. Reading. Facts. All matter. https://t.co/nPSdjtWUqq
Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183 Cleveland Clinic. ‘Ozempic Face’: - https://t.co/gNKDU9kqVg
@NftFlood @williedunnam @Paddy_Barrett @grok https://t.co/fLos8o7q3A
@KekW93757223 @GaintrustMikey @AJA_Cortes https://t.co/joCLFBb5sV
@holegots 你可能属于那 13.6% 的无反应人群 官方的研究论文：https://t.co/z8s6FJSIZk 其实他们官网标注的这类人群比例还要更高点 https://t.co/bcjkSbpqqf
RT @raphaels7: Taking 2.4 mg of semaglutide (Ozempic) for 68 weeks resulted in a reduction of food intake and a loss of nearly 17% of body…
RT @raphaels7: Taking 2.4 mg of semaglutide (Ozempic) for 68 weeks resulted in a reduction of food intake and a loss of nearly 17% of body…
RT @raphaels7: Taking 2.4 mg of semaglutide (Ozempic) for 68 weeks resulted in a reduction of food intake and a loss of nearly 17% of body…
RT @raphaels7: Taking 2.4 mg of semaglutide (Ozempic) for 68 weeks resulted in a reduction of food intake and a loss of nearly 17% of body…
RT @raphaels7: Taking 2.4 mg of semaglutide (Ozempic) for 68 weeks resulted in a reduction of food intake and a loss of nearly 17% of body…
RT @raphaels7: Taking 2.4 mg of semaglutide (Ozempic) for 68 weeks resulted in a reduction of food intake and a loss of nearly 17% of body…
RT @raphaels7: Taking 2.4 mg of semaglutide (Ozempic) for 68 weeks resulted in a reduction of food intake and a loss of nearly 17% of body…
RT @raphaels7: Taking 2.4 mg of semaglutide (Ozempic) for 68 weeks resulted in a reduction of food intake and a loss of nearly 17% of body…
RT @raphaels7: Taking 2.4 mg of semaglutide (Ozempic) for 68 weeks resulted in a reduction of food intake and a loss of nearly 17% of body…
All these new age "health messiahs" will be obliterated by ozempic https://t.co/jIr5TsIWd8 https://t.co/aAYSII1aDA
@RaMbuzZy_ https://t.co/jIr5TsIWd8
2. First, the basics: GLP-1 drugs (Ozempic, Wegovy) were developed for diabetes—but blew up as miracle weight-loss meds. They work incredibly well: semaglutide users lose ~15% body weight in just over a year. https://t.co/HXN7imNq2c
وش تقول الدراسات؟ في دراسة STEP-1 (نُشرت في NEJM): المرضى خسروا 14.9٪ من وزنهم خلال 68 أسبوع مقابل 2.4٪ فقط لمجموعة الدواء الوهمي وأكثر من ثلث المشاركين خسروا 20٪ من وزنهم! نتائج قوية جدًا. https://t.co/lK18LvVbzy
@kineyDE https://t.co/0N4xudWdaD BMI 37,8--->BMI 32,2 https://t.co/t2NFwm6wg0 BMI 35,8--->BMI 32,2 https://t.co/8hlaRr0mPC BMI 38,1--->BMI 32,1 Kurzgesagt: Man ist nach Ozempic immer noch fett, bloß einfach nicht mehr so schlimm.
Let’s start with what most people do hear about: nausea, vomiting, and diarrhea. But did you know it’s affecting nearly HALF of people on Ozempic—and for many, it’s severe enough to send them to the ER? https://t.co/dqcVOG8dJP
RT @NefroClassMx: Estudio STEP 2 Wegovy (semaglutida 2.4 mg) en DM2 + obesidad: – HbA1c: –1.6% – Peso: –9.6% – HbA1c <7%: 69% vs. 29% (pl…
Estudio STEP 2 Wegovy (semaglutida 2.4 mg) en DM2 + obesidad: – HbA1c: –1.6% – Peso: –9.6% – HbA1c <7%: 69% vs. 29% (placebo) – p<0.001 doi:10.1056/NEJMoa2032183 https://t.co/iOruc3au3r
@MohammedAlo Agreed.. The study for GLP1 weight loss included lifestyle interventions for everyone, and then compared placebo vs the GLP1. As with any intervention, there are costs and other benefit/risks to consider, but GLP1 definitely have a net benefit for many. https://t.co/BOyVRJyOOs
@JeanClaudeFox2 @KirkegaardEmil It's in the trial data, like STEP 1 here, and far less alarming than fearmongers make it out to be (mainly by misconstruing what "lean mass" is). https://t.co/lg01cx3xrs
Once-Weekly Semaglutide in Adults with Overweight or Obesity #weightloss https://t.co/1kcHZk7hSp
RT @TheMFingCOO: Clinical trials, such as the STEP 1 trial (Wilding et al., 2021, DOI: 10.1056/NEJMoa2032183), report an average weight los…
Clinical trials, such as the STEP 1 trial (Wilding et al., 2021, DOI: 10.1056/NEJMoa2032183), report an average weight loss of 5–10% of body weight over 68 weeks when used off-label for weight loss. For a 220-pound (100 kg) individual, this translates to 11–22 pounds (5–10 kg) https://t.co/6bcVzryn1Q https://t.co/Fu7IWSOvZL
@thelowcarb_rd @DrPaulMason >never mentioned it in the paper There are six mentions of "DXA" in the article. https://t.co/lg01cx3xrs
@DrPaulMason >41% of the total weight lost appeared to come from muscle and bone. No. 38.6% came from LEAN MASS. This isn't just muscle and bone. You should know this. Also funny: 57.1% came from lean mass on placebo. Very dangerous, that saline. https://t.co/lg01cx3xrs https://t.co/giu8VWq0IY
https://t.co/f1ZKS6evSv
Assuming control arm produces similar results to previous a Sema study where 6.12 kg of lean body mass is lost (40% of 15.3 kg) by 68 weeks and that 49% of total weight loss occurs by a 16 week period… https://t.co/QW9K1K24HC We can thus expect to see ~3 kg of lean body mass https://t.co/ZesSdcrwZz
@RomanRussy גם סמגלוטייד וגם טירזפטיד.סמגלוטיד(וויגובי) מטריד במיוחד לאור absolute risk increase של 3% ל SAEs בניסוי הפיבוטלי,שמשמעותו NNH של סביב 30. אבל בכל מקרה, יש הבדל בין לתת את זה לחולים במחלות כרוניות, לבין לתקוע את זה לכל אדם שני, for life, כמו שעושים עכשיו https://t.co/NERh1bMq9w https://t.co/8v1HDQAfHi
@MdBreathe Wow!! That is literally better than semaglutide, titrating up to highest dose for 60 weeks! Average weight loss was ~15% in obese patients! https://t.co/wa2TPB8g7I
@fuck_gubop К сожалению, если ты утвержатешь про "Я даже не помню исследований на людях без диабета" ты абсолютно не владеешь темой и не умеешь работать с источникам. Вот исследование на людях с ожирением в самом престижном медицинском журнале в мире. https://t.co/Z9cSupdN7Z
@apstrusus84 @Jack_de_Rivia @benryanwriter @MsYAxisLabel @acechhh Nope. These are easy to find btw. You can just google it and it comes up in the first few links. https://t.co/t9TgFkXewo
@AsafLevyHUJI 5. התעלמות מנזקים מאוד משמעותיים בניסויים קליניים (סדר גודל של 1/30 מטופלים יחווה SAE כתוצאה מהטיפול). https://t.co/lileIUAtby https://t.co/VmUF0ZL0F5
Ozempic vs Nature's Ozempic https://t.co/bcgisYeFTA via @YouTube
RT @Metabolic_Mind: @elonmusk We should consider that "losing weight" isn't always the best goal, and how we lose weight and what type of w…
RT @Metabolic_Mind: @elonmusk We should consider that "losing weight" isn't always the best goal, and how we lose weight and what type of w…
RT @Metabolic_Mind: @elonmusk We should consider that "losing weight" isn't always the best goal, and how we lose weight and what type of w…
RT @Metabolic_Mind: @elonmusk We should consider that "losing weight" isn't always the best goal, and how we lose weight and what type of w…
7. A substantial amount (~40%) of the weight lost while taking the drug is from fat-free mass, including muscle and bone. https://t.co/W4uxMsgZvF These drugs are another set of bad pharmaceutical products. https://t.co/EKnXzjsOQr
RT @Metabolic_Mind: @elonmusk We should consider that "losing weight" isn't always the best goal, and how we lose weight and what type of w…
@elonmusk We should consider that "losing weight" isn't always the best goal, and how we lose weight and what type of weight we lose may matter more. Here's a short video we did on this topic https://t.co/RyIVdhqG2n
@REGENETARIANISM @HeatherEHeying Nothing in that thread that really outweighs the reduction in mortality. I think people are trying very hard to land a hit on this drug and "long-term unknowns" are the sort of argument of last resort. Even some linked papers he uses... are supportive! https://t.co/JJAMbxrhf4
@JeepzRock10 @GailAlfarATX On GLP-1 receptor agonists like Semaglutide. https://t.co/RrDfRv2iff https://t.co/bsMR3Bo9Me
@nothanksnopeyno @VamosRafa66 @zoeytshade @st_canary @Gabepluguez It’s been approved, done and published. https://t.co/WZMLnWcMZo
No. Hay estudios de eficacia y seguridad también para el sobrepeso. https://t.co/NhXnNADnvy https://t.co/S7vnpijqQ2 No es una droga mágica. Simplemente por su mecanismo te suprime el apetito bastante. Si sigues comiendo lo de antes sin apetito vas a engordar igual xd https://t.co/WDN0DLeBNU
@ByronKAdamsX @BettaVirtual @AP https://t.co/wZTDWL3Vih
RT @carpe_diem0820: 2型糖尿病の治療薬として承認されている注射用セマグルチドを糖尿病ではない肥満成人に生活習慣の改善と併用することで5%以上の体重減少達成率が優位に上昇(86% vs 33%) 一方、胆石症のリスクが増加 Once-Weekly Semag…
Once-Weekly Semaglutide in Adults with Overweight or Obesity | New England Journal of Medicine https://t.co/zg3Jpvee5D
@YaffaRaz שאלתי את https://t.co/GCl1bZ9rvZ מה דעתו על המחקר הזה: https://t.co/lileIUzVm0 היו לו תשובות מעניינות. https://t.co/FOu4sTf6hm
@iajlbee @rkylesmith …lose weight. And no, energy balance has not “failed” in clinical trials. Methods of achieving deficit have failed, but not the principle of EBM, which is absolute and more fundamental than any biochemical mechanism. https://t.co/Pxh10lS0Go
- https://t.co/2PkzC0euTK
Participants with overweight or obesity, 2.4 mg of semaglutide once weekly, and lifestyle intervention were associated with sustained, clinically relevant reduction in body weight. @ww_us https://t.co/c1HjAcXsul?
WILDING, J. P. H et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine, v. 384, n. 11, fev. 2021. Dísponivel: www.nejm.org/doi/full/10....
@cremieuxrecueil https://t.co/32nDPUq3sD In 140 patients, mean fat loss was 8.36 kg, lean mass loss was 5.26 kg. post-weight loss resting metabolic rates will be lower. a similar reason why most yo-yo diets fail in the long run.
Once-Weekly Semaglutide in Adults with Overweight or Obesity: https://t.co/NnX6bqxFd0 Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension https://t.co/NPkIej9Oy3 #NoMoreCovidDeaths #LongCovid #wastewater #JN1 #H5N1 #coronavirus
@tigbit1337 @JohnWat59766564 @KincaidTerrill @GiaMMacool You'd have a better argument pushing ozempic (semaglutide). It works (with side effects) far more effectively than surgery. New advances in medicine and medical tech changes and improves constantly. Link on Ozempic (semaglutide) for weight loss https://t.co/JvHBMdVkA3
@vicentmarti_ @IbaiLlanos El único "pero" es que se también pierde masa muscular. Incluso los estudios de Novo Nordisk dicen eso. https://t.co/L2me1d3MDb
@abo_3dnan_44 @Faisal_Science @Rocky_ioi https://t.co/idUGwEJv2n https://t.co/rKcHdHPQAg https://t.co/8q4AB5H0kT The STEP 1 trail you can find the data needed in: Supplementary Appendix, Table S5 https://t.co/ckxviqI84Y
@JustinTaylorBE @LinkofSunshine Wtf is this then? https://t.co/nvN5kRcXAu
@fivehundredpou1 Ozempic, known generically as semaglutide. NCT03548935 Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity | https://t.co/OE4FczoV0g NEMJ "Once-Weekly Semaglutide in Adults with Overweight or Obesity" (https://t.co/TXuXGIjvAn)
Once-Weekly Semaglutide in Adults with Overweight or Obesity #weightlosss https://t.co/1kcHZk7hSp
@Brettheepi Once-Weekly Semaglutide in Adults with Overweight or Obesity Wilding, J. P. H., et al. (2021). “Once-weekly semaglutide in adults with overweight or obesity.” New England Journal of Medicine, 384(11), 989-1002. https://t.co/kkWSEntD0Y
@liveatspotlight @thecaptain_nemo It’s very tested https://t.co/hopZhc3VNm https://t.co/IHQVkCQpuk
@RaymondMoore89 @HilldurG @anymanfitness @MattWalshBlog You’re joking with that source right? GTFO, you’re clearly a troll. I know you won’t open it and have never read an actual trial, but here ya go. https://t.co/ociAGk58Zv
@deportriggers @MichaelAlbertMD Here https://t.co/Trxm9AleVB
@Rohan65336929 @222RELOADED @doxie_gay sorry, i don’t know what happened, let’s try again: https://t.co/02usxZcBoK https://t.co/d3fJUlmzjF second one is called: “Beyond Ozempic: brand-new obesity drugs will be cheaper and more effective” in case it doesn’t load now
@aleksoap @222RELOADED @doxie_gay it can be used for obesity: https://t.co/02usxZcBoK
https://t.co/sALW7T9LOT
https://t.co/sALW7T9LOT
@SebLin10 https://t.co/gIYgW1TQ4s
@ZKForTre was ~40% of the lost weight coming from lean body mass like it did for 2.4 mg/week semaglutide? https://t.co/O7Nn7x88ve or has this new generation of fat-loss drugs improved the ratio of lean body mass to fat mass lost? https://t.co/1NGHUFgb22
https://t.co/NjThVbMlMb
@MohammedAlo @Alicewants2know https://t.co/r5fHQkenK0
When studies like
@thereallsu777 @DrNadolsky And here is the Step 1 paper from the New England Journal of Medicine showing a 39.77% muscle mass loss (of total weight loss). This is two times the amount of muscle loss seen in other approaches to weight loss. https://t.co/1jvsaJQUNt There are groups who see a 50% muscle
@ElliotStabler92 Die Studien dazu sind grauenhaft. Ozempic, Wirkstoff Semaglutide. Natürlich vom Herrsteller. Interessenskonflikte sind egal heutzutage. Selbst diese listet viele schwere Nebenwirkungen wie zb.. https://t.co/hco4zpLt2K Medikamentenwerbung war mal verboten. Lange her. -.- https://t.co/MxbgRkfNc6
RT @thesamparr: Study: https://t.co/M637mJLmP5
@fernandaimamura Sabemos . Tem estudo. A semaglutida já está aprovada pelo fda e pela anvisa . Só que por fins puramente comerciais , o ozempic e vendido para diabetes , e o wegovy para emagrecimento . A única diferença entre eles é a dose , e do wegovy é maior . https://t.co/VWLnzO8jqN
@fernandaimamura Veja esse estudo: https://t.co/WmbrAdPvpH
The medications are a breakthrough--no question about it! But GLPs don't make you fit. Your sleep, neurologic/cognitive function, digestive function, musculoskeletal ease of use are all impacted by your level of fitness. Link in Bio-Full Episode 41 https://t.co/MGxnmfUbVE https://t.co/F21T0fuKmP
It's more than CALORIES IN - CALORIES OUT. But CALORIES IN - CALORIES OUT matters. The scientific underpinning of weight loss remains but we shouldn't trivialize the attainment of healthy body weight to an equation. See the full explanation: https://t.co/ecrPQdb5FE (Link in Bio) https://t.co/bAii8HTmiH
It's more than CALORIES IN - CALORIES OUT. But CALORIES IN - CALORIES OUT matters. The scientific underpinning of weight loss remains but we shouldn't trivialize the attainment of healthy body weight to an equation. See the full explanation: https://t.co/ecrPQdb5FE (Link in Bio) https://t.co/qblfbbF6tu
☕ Body Positive: Dr. Safai brings body image issues into the conversation about the use of the breakthrough GLP-1 drugs, like #Ozempic or #Wegovy or #Zepbound or #mounjaro Follow @healthmasterycafe See the full interview: https://t.co/ecrPQdb5FE (Link in Bio) https://t.co/LQUDLwPWPZ
☕️Should people with a normal body weight/BMI get prescriptions for #Wegovy or #Ozempic from their physicians? Watch the full video for a new perspective on this. See the full explanation: https://t.co/ecrPQdb5FE (Link in Bio) Follow @healthmasterycafe or on X @masterycafe https://t.co/2ZO2MDccGb
Body Image ☕ Body Positive: Dr. Safai brings body image issues into the conversation about the use of the breakthrough GLP-1 drugs, like #Ozempic or #Wegovy or #Zepbound or #mounjaro Follow @healthmasterycafe See the full interview: https://t.co/ecrPQdb5FE (Link in Bio) https://t.co/RxXHuZMrlH
@ReneAyalaV @Isco_Rmc @alexxbcc https://t.co/fli004ZI2m
☕️☕️ Sip on this with us: Brewing Confidence- Follow The Health Mastery Cafe to catch every drop of knowledge about self-care and confidence! Follow the page
☕️Should people with a normal body weight/BMI get prescriptions for #Wegovy or #Ozempic from their physicians? The answer to this question may surprise you? Watch this clip.. Follow @healthmasterycafe See the full explanation: https://t.co/ecrPQdb5FE (Link in Bio) https://t.co/J1wyy0N2SB
@hafu_ilustra Alguns estudos mostrando uso de semaglutida (composto da ozempic) para emagrecimento. https://t.co/GM42ZDvi1F https://t.co/wbpl1h27o9 https://t.co/KIbo1Q13PX
@jadebutterfiel8 @reflexmd_com Here is ONE of the studieS that showed this. https://t.co/Ti8s2ql8Tr
@peterpham @MViggars 1mg study: https://t.co/6hffe18wIa 2.4mg study: https://t.co/gZaqYO3caG Review on lean mass lost during a diet or bariatric surgery: https://t.co/XmTsOE5dWX
@StevenMBelknap @TamarHaspel The large-scale trials tested semaglutide against lifestyle and diet counseling, no? https://t.co/1itCCczfjB https://t.co/LikIeUMdOv
@TamarHaspel 40% of weight lost with Ozempic is lean mass. https://t.co/46Jcdx3ilw
PMID: https://t.co/0ofwV7uUnd https://t.co/z6XN13nY25
@BethLorigan @calleymeans Cool story Beth Anne, but they've done studies on the subject. Get your facts straight. "The mean change in body weight from baseline to week 68 was −14.9% in the semaglutide group as compared with −2.4% with placebo" https://t.co/Zgeey8GWUX
https://t.co/cz3sWCMpTZ
RT @carpe_diem0820: 2型糖尿病の治療薬として承認されている注射用セマグルチドを糖尿病ではない肥満成人に生活習慣の改善と併用することで5%以上の体重減少達成率が優位に上昇(86% vs 33%) 一方、胆石症のリスクが増加 Once-Weekly Semag…
Interested in studies that looked at RCTs on the efficacy of semaglutide on obese patients with or without DMT2? Also interested in double blind studies that do the same? https://t.co/pY7RcbMJz9 https://t.co/WG82PAckIV
Ozempic vs #Nature's Ozempic #plant #plants https://t.co/cCQz71UkWn #video #YouTube
@shengxj1 Probably this will answer you https://t.co/S3sHoisdym
@buccocapital This is not a problem. https://t.co/aXAFqdyafo Supplementary Appendix looked at muscle and fat loss as a % - almost all weight loss was fat mass.
Check out this study on semaglutides
https://t.co/r5AOI1rPrP
El desafío del mantenimiento a largo plazo de reducción de peso sigue sin resolverse dado que con semaglutida y/o tirzepatida se puede llegar a
RT @hellokidneyMD: ✅ The dose used in the study was 2.4 mg of semaglutide once weekly. This is much higher than your 0.5 mg dose of Ozempic…
✅ The dose used in the study was 2.4 mg of semaglutide once weekly. This is much higher than your 0.5 mg dose of Ozempic ✅ This means to achieve similar results, one has to buy 5 x 0.5 mg doses per week. For 68 weeks. Do the math. It ain’t cheap. https://t.co/x5oWtiYBZ2
https://t.co/gHFgax9Kk7
RT @raphaels7: Taking 2.4 mg of semaglutide (Ozempic) for 68 weeks resulted in a reduction of food intake and a loss of nearly 17% of body…
@holajool Nesse caso foi uma reportagem da revista Science, abaixo seguem as referências para os estudos das drogas citadas. Wilding J. et al - Once-Weekly Semaglutide in Adults with Overweight or Obesity DOI: 10.1056/NEJMoa2032183 Jastrrboff A. et al - Tirzepatide Once Weekly for the
@PeterDilworth1 @BorisJohnson @RishiSunak @Conservatives @VictoriaAtkins @CMO_England @UKHSA He’s injecting Semaglutide… https://t.co/yMNYWyTPzy
Once-Weekly Semaglutide in Adults with Overweight or Obesity | NEJM https://t.co/tUYKvC3jGl
@theproof More whole grains = less addiction. No matter what type of addiction. Works with other fiber sources too but not as well as rye etc. Ozempic vs Nature's Ozempic https://t.co/JGv6Ryx76V
RT @NutritionMadeS3: New video: All about OZEMPIC (semaglutide), WEGOVY, MOUNJARO (tirzepatide) Are GLP-1 analogues safe? How do they wor…
Güzel bir video https://t.co/0Jw5sGnD4h
@MauBataller @MediCasos https://t.co/cyhkerILOk @NEJM
@BidaFialova @iDNEScz Podle studie došlo k redukci váhy o 15% (v porovnání s 2% ztrátou váhy v případě podávání placeba). Ovšem ve významně vyšších (= 5x) dávkách než je tento lék (určený pro diabetes 2. typu). Toto je jen virální záležitost... https://t.co/tqIM5mn2Fj
Once-Weekly Semaglutide in Adults with Overweight or Obesity. https://t.co/vvTFvXg8OJ
RT @1cavemank: @HedgeDirty Unless it magically became far more effective than it was in the studies, it's not going to do anything. It to…
@HedgeDirty Unless it magically became far more effective than it was in the studies, it's not going to do anything. It took subjects in this study 68 weeks (!!) to lose just 34 lbs. Mean BMI was 38 and only dropped by 6. Obese stayed obese, 15 months later. https://t.co/VFRRJz3MJg https://t.co/R8h8lfRFzA
RT @MDBitcoin: Here are studies if you want to read more about this: Clinical Review Report: Semaglutide (Ozempic) - NCBI https://t.co/acZ…
RT @MDBitcoin: Here are studies if you want to read more about this: Clinical Review Report: Semaglutide (Ozempic) - NCBI https://t.co/acZ…
RT @MDBitcoin: Here are studies if you want to read more about this: Clinical Review Report: Semaglutide (Ozempic) - NCBI https://t.co/acZ…
RT @MDBitcoin: Here are studies if you want to read more about this: Clinical Review Report: Semaglutide (Ozempic) - NCBI https://t.co/acZ…
Here are studies if you want to read more about this: Clinical Review Report: Semaglutide (Ozempic) - NCBI https://t.co/acZ9oq7FXk Once-Weekly Semaglutide in Adults with Overweight or Obesity - PubMed https://t.co/qP428ORFvc Semaglutide (Ozempic) for weight loss - PubMed
https://t.co/n1noSp3gVV Semaglutida una vez a la semana en adultos con sobrepeso u obesidad En participantes con sobrepeso u obesidad, 2,4 mg de semaglutida una vez a la semana más la intervención en el estilo de vida se asociaron con una reducción sostenida y clínicamente
@DrFrankLipman That's like people who eat a lot of whole grains and fruits? https://t.co/XwecQYOGqx
RT @carpe_diem0820: 2型糖尿病の治療薬として承認されている注射用セマグルチドを糖尿病ではない肥満成人に生活習慣の改善と併用することで5%以上の体重減少達成率が優位に上昇(86% vs 33%) 一方、胆石症のリスクが増加 Once-Weekly Semag…
@TamarHaspel Nature vs drug https://t.co/HdZgYOshY8
Intermittent Fasting COMPLETELY Reverses Type 2 Diabetes https://t.co/G3NvpL6Pgx via @YouTube
Is Berberine REALLY Nature's Ozempic?
RT @BradStanfieldMD: References: https://t.co/ifEDAxTBYn https://t.co/cuht9mtbqp https://t.co/vpEzuNCUFf https://t.co/lpHy2pBHLH
References: https://t.co/ifEDAxTBYn https://t.co/cuht9mtbqp https://t.co/vpEzuNCUFf https://t.co/lpHy2pBHLH
Once-Weekly Semaglutide in Adults with Overweight or Obesity https://t.co/1kcHZk7hSp
@Nutradvance Starches and fruits are nature's Ozempic as they boost GLP-1 https://t.co/JGv6Ryx76V
@TamarHaspel Fruits and grains and keeping saturated fats lows performs better than Ozempic. And at a much lower price... Ie people want Ozempic
@TamarHaspel Eat whole grains and fruits and avoid saturated fats instead. Much cheaper and more effective. https://t.co/JGv6Ryx76V
More whole grains, more fruits, less saturated fats. The basics that everyone loves to ignore basically? How many want to lose weight and start eating low-carb and high-fat/protein?
RT @NeilFlochMD: Once-Weekly Semaglutide in Adults with Overweight or Obesity | @NEJM https://t.co/1xEHmlQqEy
RT @NeilFlochMD: Once-Weekly Semaglutide in Adults with Overweight or Obesity | @NEJM https://t.co/1xEHmlQqEy
RT @NeilFlochMD: Once-Weekly Semaglutide in Adults with Overweight or Obesity | @NEJM https://t.co/1xEHmlQqEy
RT @NeilFlochMD: Once-Weekly Semaglutide in Adults with Overweight or Obesity | @NEJM https://t.co/1xEHmlQqEy
Once-Weekly Semaglutide in Adults with Overweight or Obesity | @NEJM https://t.co/1xEHmlQqEy
#Weightloss drugs present more questions than answers, but they could be a key tool in reducing the obesity epidemic @ConversationEDU https://t.co/KBlWYnwkRG https://t.co/aUGs2RR7Z5
RT @carpe_diem0820: 2型糖尿病の治療薬として承認されている注射用セマグルチドを糖尿病ではない肥満成人に生活習慣の改善と併用することで5%以上の体重減少達成率が優位に上昇(86% vs 33%) 一方、胆石症のリスクが増加 Once-Weekly Semag…
Also, why?! 68 weeks to lose 34 pounds?! If a personal trainer gave you those results, you would (rightfully) fire them. This is supposed to be success? Mean BMI was about 38 and mean BMI drop was less than 6. So obese folks stayed obese! (From: https://t.co/VFRRJz3MJg) https://t.co/smsEptrpzN
@EstebanDL Yo estoy confundido con lo que averiguo sobre esa droga. Por un lado me parece un disparate médico su indicación, y por el otro aparecen infos como ésta en publicaciones serias. No entiendo https://t.co/MVBZges6Nk
@hi_im_marquii @el_pais De sus propiedades para el manejo de la diabetes https://t.co/4s1yURyQnw https://t.co/zL8WBXzG8S
The New Weight Loss Drugs OZEMPIC, MOUNJARO (semaglutide, tirzepatide) |... https://t.co/qoKUgbf6Rt via @YouTube
RT @NutritionMadeS3: New video: All about OZEMPIC (semaglutide), WEGOVY, MOUNJARO (tirzepatide) Are GLP-1 analogues safe? How do they wor…
RT @DudzLightLime: The New Weight Loss Drugs OZEMPIC, MOUNJARO... https://t.co/8TTpdV3GlI via @YouTube Excellent interview w/ @DrNadolsky…
RT @NutritionMadeS3: New video: All about OZEMPIC (semaglutide), WEGOVY, MOUNJARO (tirzepatide) Are GLP-1 analogues safe? How do they wor…
RT @NutritionMadeS3: New video: All about OZEMPIC (semaglutide), WEGOVY, MOUNJARO (tirzepatide) Are GLP-1 analogues safe? How do they wor…
RT @DudzLightLime: The New Weight Loss Drugs OZEMPIC, MOUNJARO... https://t.co/8TTpdV3GlI via @YouTube Excellent interview w/ @DrNadolsky…
RT @NutritionMadeS3: New video: All about OZEMPIC (semaglutide), WEGOVY, MOUNJARO (tirzepatide) Are GLP-1 analogues safe? How do they wor…
RT @NutritionMadeS3: New video: All about OZEMPIC (semaglutide), WEGOVY, MOUNJARO (tirzepatide) Are GLP-1 analogues safe? How do they wor…
What happens when Gil @NutritionMadeS3 interviews Spencer @DrNadolsky re: "The New Weight Loss Drugs OZEMPIC, MOUNJARO (semaglutide, tirzepatide)"?
The New Weight Loss Drugs OZEMPIC, MOUNJARO... https://t.co/8TTpdV3GlI via @YouTube Excellent interview w/ @DrNadolsky and @NutritionMadeS3. I couldn’t agree more the robust relief some patients experience from the intrusive thoughts about food. Life changing for some.
New video: All about OZEMPIC (semaglutide), WEGOVY, MOUNJARO (tirzepatide) Are GLP-1 analogues safe? How do they work? What about side effects? Will they change the reality of public health? ft. @DrNadolsky https://t.co/GC16bHlYAx
@RonaldF47679601 @andrwrdr https://t.co/ueWyFAjwR3
Once-Weekly Semaglutide in Adults with Overweight or Obesity | NEJM https://t.co/DJgsy1SVpG
RT @balsm_24: علاج اوزمبيك … https://t.co/uW2D06veU6 https://t.co/cHJhy8iUzf
RT @balsm_24: علاج اوزمبيك … https://t.co/uW2D06veU6 https://t.co/cHJhy8iUzf
علاج اوزمبيك … https://t.co/uW2D06veU6 https://t.co/cHJhy8iUzf
https://t.co/cS6uUw0NiF
減量の為のWegovy https://t.co/gRA3V4i2YA 過体重or肥満の成人:週1回Semaglutide https://t.co/vECNKvA91t 体重⬇️持続 製造会社は医学的問題を抱える肥満⬇️主張 Novo Nordiskは2型糖尿病や慢性疾患の減量を助け、体重維持可と主張
Once-Weekly Semaglutide in Adults with Overweight or Obesity | NEJM https://t.co/IU2njoznaf
Once-Weekly Semaglutide in Adults with Overweight or Obesity | NEJMj @jsmadero @germanfajardo @JRBneuropsiq https://t.co/Jne1hzGeTL
https://t.co/PFNwir2nwD
Intermittent Fasting COMPLETELY Reverses Type 2 Diabetes https://t.co/kEXCODGjUK via @YouTube
https://t.co/Wu5wiUTdZ7
@rohan_aziz_ https://t.co/hrbnBexZzP promising data though...
And how can we not talk about improvements in pharmacotherapy? Semaglutide is deemed a "game changer", showing wt losses that parallel surgery (average 15% & more than 1/3 lost >20% of their weight). And let's not forget the amazingness of Tirzepatide. https://t.co/6QiY6Kob2m
43b) STEP1 is at
@pepesgrandma I read that study in NEJM. Once-Weekly Semaglutide in Adults with Overweight or Obesity https://t.co/HLPxjoGrWr Encouraging for the following (and unlike bariatric surgery which can have nasty permanent side effects, this can be stopped any time): https://t.co/JYdJ7KTEzu
RT @AmCollegeGastro: 1/ Ready for another #EBGI Tweetorial
RT @AmCollegeGastro: 1/ Ready for another #EBGI Tweetorial
RT @michaelmantzmd: Interesting Weight Loss Study (RCT) 2021 Semaglutide 2.4mg injection once a week + lifestyle coaching Average Weight…
Interesting Weight Loss Study (RCT) 2021 Semaglutide 2.4mg injection once a week + lifestyle coaching Average Weight Loss Semaglutide group: -34 lbs Placebo group: -6 lbs Once-Weekly Semaglutide in Adults with Overweight or Obesity | NEJM https://t.co/NSYuAl7LvY
RT @AmCollegeGastro: 1/ Ready for another #EBGI Tweetorial
RT @AmCollegeGastro: 1/ Ready for another #EBGI Tweetorial
RT @AmCollegeGastro: 1/ Ready for another #EBGI Tweetorial
RT @AmCollegeGastro: 1/ Ready for another #EBGI Tweetorial
RT @AmCollegeGastro: 1/ Ready for another #EBGI Tweetorial
RT @AmCollegeGastro: 1/ Ready for another #EBGI Tweetorial
RT @AmCollegeGastro: 1/ Ready for another #EBGI Tweetorial
RT @AmCollegeGastro: 1/ Ready for another #EBGI Tweetorial
1/ Ready for another #EBGI Tweetorial
43b) STEP1 is at
Once-Weekly Semaglutide in Adults with Overweight or Obesity. "In participants with overweight or obesity, 2.4 mg of semaglutide once weekly plus lifestyle intervention was associated with sustained, clinically relevant reduction in body weight." https://t.co/aVLjd1Tpwh
Congratulations to Dr. Robert F Kushner @NUFeinbergMed on his award winning study "Once-Weekly Semaglutide in Adults with Overweight or Obesity"! https://t.co/ykNu724nYf #TopTen
RT @IMMWHC: Excellent Journal Club, Dweep and Malik
RT @IMMWHC: Excellent Journal Club, Dweep and Malik
Congratulations to our Top 10 awardee Dr. Robert Kushner @NUFeinbergMed on his study "Once-Weekly Semaglutide in Adults with Overweight or Obesity"!! Learn more about Obesity and the current statistics today! https://t.co/8OKyqVIeVS #NPHW #TopTen https://t.co/fQMoNDVHcR
Excellent Journal Club, Dweep and Malik
#Insight: A meta-analysis by Zhong et al. has shown that once weekly semaglutide significantly increases the proportion of patients achieving categorical weight reduction targets versus placebo. Read our slide summary for free below for more. https://t.co/9Q1rJ1WJzw
Given the rising obesity epidemic in children and it’s affects on long term health outcomes I wonder if this could be a potential option as a last resort. Once-Weekly Semaglutide in Adults with Overweight or Obesity | NEJM https://t.co/gEAWiK1TLF
GLP-1 agonists (particularly semaglutide) work incredibly for obesity. Following on from NEJM paper last year (https://t.co/oADtzYg0aH) now another RCT in JAMA: https://t.co/KEumSzEYcm $$$$$ for @novonordisk https://t.co/2Rq3NUCtcP
https://t.co/Y51NlZVoII
RT @sociedadSEEN:
RT @sociedadSEEN:
RT @sociedadSEEN:
RT @sociedadSEEN:
RT @sociedadSEEN:
RT @sociedadSEEN:
RT @sociedadSEEN:
RT @sociedadSEEN:
RT @sociedadSEEN:
- Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease - Once-Weekly Semaglutide in Adults with Overweight or Obesity - Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis
Once-Weekly Semaglutide in Adults with Overweight or Obesity REPLY https://t.co/3DBNKraVcP
RT @drjohnmorley: Once-Weekly Semaglutide in Adults with Overweight or Obesity | NEJM https://t.co/QqXwGW8aKA
Once-Weekly Semaglutide in Adults with Overweight or Obesity | NEJM https://t.co/QqXwGW8aKA
RT @AmCollegeGastro: In Evidence-Based GI: Once-Weekly Semaglutide in Adults with Overweight or Obesity Reviewers: Dr. Philip Schoenfeld &…
RT @AmCollegeGastro: In Evidence-Based GI: Once-Weekly Semaglutide in Adults with Overweight or Obesity Reviewers: Dr. Philip Schoenfeld &…
RT @AmCollegeGastro: In Evidence-Based GI: Once-Weekly Semaglutide in Adults with Overweight or Obesity Reviewers: Dr. Philip Schoenfeld &…
RT @AmCollegeGastro: In Evidence-Based GI: Once-Weekly Semaglutide in Adults with Overweight or Obesity Reviewers: Dr. Philip Schoenfeld &…
In Evidence-Based GI: Once-Weekly Semaglutide in Adults with Overweight or Obesity Reviewers: Dr. Philip Schoenfeld & Dr. Sonali Paul Article: https://t.co/tXhbDDabw9 Audio Summary: https://t.co/JWNWw3jORj @DrJessicaA @JenKolbMD @KumarShria @PhilipOkaforMD @spaulliver @swatigp https://t.co/g7Ktr2NrXf
Open Access UCL Research: Once-Weekly Semaglutide in Adults with Overweight or Obesity https://t.co/3lwxqNlZnD
NovoNordisk about to make so much money off this drug, honestly terrifying. Once-Weekly Semaglutide in Adults with Overweight or Obesity | NEJM https://t.co/fAiRjuvOeR
Once-Weekly Semaglutide in Adults with Overweight or Obesity | NEJM https://t.co/slvcFLwuED
Once-Weekly Semaglutide in Adults with Overweight or Obesity https://t.co/HO1NyAc7jF
RT @RosenelliEM: Tonight on @UnremarkableLab, we discussed weight loss and GLPs. @mendesthiagob shared this gem. Once-Weekly Semaglutid…
RT @RosenelliEM: Tonight on @UnremarkableLab, we discussed weight loss and GLPs. @mendesthiagob shared this gem. Once-Weekly Semaglutid…
RT @RosenelliEM: Tonight on @UnremarkableLab, we discussed weight loss and GLPs. @mendesthiagob shared this gem. Once-Weekly Semaglutid…
Tonight on @UnremarkableLab, we discussed weight loss and GLPs. @mendesthiagob shared this gem. Once-Weekly Semaglutide in Adults with Overweight or Obesity | NEJM https://t.co/w0m8ZOPrD9
RT @DBelardoMD: The game changing trial we are discussing is “Once-Weekly Semaglutide in Adults with Overweight or Obesity” with lead autho…
RT @readatidbit: Weekly semaglutide as a treatment option for obesity? Participants in the treatment arm of this RCT achieved a 14.9% mean…
RT @DBelardoMD: The game changing trial we are discussing is “Once-Weekly Semaglutide in Adults with Overweight or Obesity” with lead autho…
RT @DrPess: ✅ Semaglutide just approved for long-term weight loss by @US_FDA ✅ Average weight ⬇️ 15% (~34 pounds) in @NEJM study (by week…
RT @DBelardoMD: The game changing trial we are discussing is “Once-Weekly Semaglutide in Adults with Overweight or Obesity” with lead autho…
Once-Weekly Semaglutide in Adults with Overweight or Obesity. Reply. https://t.co/3DBNKraVcP
RT @TimothyWSchwab: In #NEJM, @DrRobertKushner discloses "receiving advisory board fees from @NovoNordisk," correct? Why would NYT put his…
RT @TimothyWSchwab: In #NEJM, @DrRobertKushner discloses "receiving advisory board fees from @NovoNordisk," correct? Why would NYT put his…
RT @TimothyWSchwab: In #NEJM, @DrRobertKushner discloses "receiving advisory board fees from @NovoNordisk," correct? Why would NYT put his…
In #NEJM, @DrRobertKushner discloses "receiving advisory board fees from @NovoNordisk," correct? Why would NYT put his voice at center of article promoting NovoNordisk obesity drug----and not disclose his ties to the company? What am I missing? https://t.co/6er1DBpSCM https://t.co/TSpq6C0JjO
Once-Weekly Semaglutide in Adults with Overweight or Obesity | NEJM https://t.co/FzGBRfe8Ft
New post in Development of Pharmacy Channel: Once-Weekly Semaglutide in Adults with Overweight or Obesity https://t.co/LARvNG3PIy https://t.co/Prhycn3LVz
RT @Phresidency: We enjoyed our virtual clinical hour titled “Once-Weekly Semaglutide in Adults with overweight or obesity” presented by Dr…
We enjoyed our virtual clinical hour titled “Once-Weekly Semaglutide in Adults with overweight or obesity” presented by Dr. Malak Aldahash, PGY1 #RxTwitter https://t.co/ZMaiUekSFL
RT @DrPess: ✅ Semaglutide just approved for long-term weight loss by @US_FDA ✅ Average weight ⬇️ 15% (~34 pounds) in @NEJM study (by week…
RT @DrPess: ✅ Semaglutide just approved for long-term weight loss by @US_FDA ✅ Average weight ⬇️ 15% (~34 pounds) in @NEJM study (by week…
@isolapine https://t.co/Kr2ZZAbQdK une des publi sur le semaglutide.
New @US_FDA approved medication promoting nearly 15% weight loss in 68 weeks when combined with reduced caloric intake and exercise. Once-Weekly Semaglutide in Adults with Overweight or Obesity | NEJM https://t.co/iTxCex7FRu
RT @CristobMorales: https://t.co/8CN3NyU741 Once-Weekly Semaglutide in Adults with Overweight or Obesity https://t.co/EhatCqEfQN FDA appro…
RT @DBelardoMD: The game changing trial we are discussing is “Once-Weekly Semaglutide in Adults with Overweight or Obesity” with lead autho…
RT @CristobMorales: https://t.co/8CN3NyU741 Once-Weekly Semaglutide in Adults with Overweight or Obesity https://t.co/EhatCqEfQN FDA appro…
RT @CristobMorales: https://t.co/8CN3NyU741 Once-Weekly Semaglutide in Adults with Overweight or Obesity https://t.co/EhatCqEfQN FDA appro…
RT @CristobMorales: https://t.co/8CN3NyU741 Once-Weekly Semaglutide in Adults with Overweight or Obesity https://t.co/EhatCqEfQN FDA appro…
RT @CristobMorales: https://t.co/8CN3NyU741 Once-Weekly Semaglutide in Adults with Overweight or Obesity https://t.co/EhatCqEfQN FDA appro…
RT @CristobMorales: https://t.co/8CN3NyU741 Once-Weekly Semaglutide in Adults with Overweight or Obesity https://t.co/EhatCqEfQN FDA appro…
RT @CristobMorales: https://t.co/8CN3NyU741 Once-Weekly Semaglutide in Adults with Overweight or Obesity https://t.co/EhatCqEfQN FDA appro…
https://t.co/8CN3NyU741 Once-Weekly Semaglutide in Adults with Overweight or Obesity https://t.co/EhatCqEfQN FDA approves obesity drug that helped people cut weight 15% @washingtonpost https://t.co/7IOilDLOwv ‘A Game Changer’: Weight Loss in Patients With Obesity @nytimes https://t.co/EJmFHbLWuE
RT @DrPess: ✅ Semaglutide just approved for long-term weight loss by @US_FDA ✅ Average weight ⬇️ 15% (~34 pounds) in @NEJM study (by week…
RT @DrPess: ✅ Semaglutide just approved for long-term weight loss by @US_FDA ✅ Average weight ⬇️ 15% (~34 pounds) in @NEJM study (by week…
✅ Semaglutide just approved for long-term weight loss by @US_FDA ✅ Average weight ⬇️ 15% (~34 pounds) in @NEJM study (by week 68) #EndoTwitter #weightloss https://t.co/Pn3ZAfeyaI https://t.co/g2OLXjlThw
@lakartidn Semaglutid på indikationen obesitas är under granskning av EMA. Kanske lite olycklig timing med nya riktlinjer just nu. https://t.co/5T8uRtJN2q
RT @tmodarressi: @InSeaSt8Fan @SeeFisch While oral semaglutide is currently FDA indicated for patients with type 2 diabetes, injectable onc…
@InSeaSt8Fan @SeeFisch While oral semaglutide is currently FDA indicated for patients with type 2 diabetes, injectable once-weekly semaglutide at a higher 2.4mg dose was studied as an anti-obesity medication in patients without diabetes and has been submitted for FDA review. https://t.co/SmIHZ4CtWK
Do you guys use GLP-1 agonists for weight loss in non-diabetic patients? This article suggests it works, and it also improves CV risk factors + functional status https://t.co/2JxsJ2070D
RT @cardiomet_CE: 11) So let's focus on overweight/obesity management and take a look at the most recent study of a GLP-1 RA in that space:…
RT @cardiomet_CE: 11) So let's focus on overweight/obesity management and take a look at the most recent study of a GLP-1 RA in that space:…
11) So let's focus on overweight/obesity management and take a look at the most recent study of a GLP-1 RA in that space: Wilding JP et al, NEJM 2021;384:989-1002. This was the STEP-1 study and you can find it at https://t.co/36QTkOpb6l.
@garytaubes @SamueleMarcora https://t.co/e5occ8H9yW
@ZaherToumi @DrHemels @IfsoSecretariat https://t.co/YJkDqSS3MJ
Today OrACORe RA @kaetlyn_arant will be presenting the results of a trial on the use of subcutaneous semaglutide in overweight and obese patients at our Journal Club! We look forward to a lively discussion. Read along with us: https://t.co/Y7Y1vu7JBR
Once-Weekly Semaglutide in Adults with Overweight or Obesity | NEJM https://t.co/pjMXsAeC1l
As a reminder, our journal article
RT @DavidACohen_MD: If you don’t have access to the article, please send me a DM and I can send you the article. https://t.co/tZ9vGFXT1K
If you don’t have access to the article, please send me a DM and I can send you the article. https://t.co/tZ9vGFXT1K
Once-Weekly Semaglutide in Adults with Overweight or Obesity | NEJM https://t.co/ENIFVKJD6a How is this not awesome? Thank you @DrRobertKushner
RT @DavidACohen_MD: ATTENTION! The next #EndoTwitter Journal Club will be next Wed, April 7 @ 830 EDT. @DrJayyy__ & @DavidACohen_MD will…
RT @DavidACohen_MD: ATTENTION! The next #EndoTwitter Journal Club will be next Wed, April 7 @ 830 EDT. @DrJayyy__ & @DavidACohen_MD will…
RT @DavidACohen_MD: ATTENTION! The next #EndoTwitter Journal Club will be next Wed, April 7 @ 830 EDT. @DrJayyy__ & @DavidACohen_MD will…
RT @DavidACohen_MD: ATTENTION! The next #EndoTwitter Journal Club will be next Wed, April 7 @ 830 EDT. @DrJayyy__ & @DavidACohen_MD will…
RT @DavidACohen_MD: ATTENTION! The next #EndoTwitter Journal Club will be next Wed, April 7 @ 830 EDT. @DrJayyy__ & @DavidACohen_MD will…
RT @DavidACohen_MD: ATTENTION! The next #EndoTwitter Journal Club will be next Wed, April 7 @ 830 EDT. @DrJayyy__ & @DavidACohen_MD will…
RT @DrPess: It’s back! #EndoTwitter Journal Club Wed, April 7th @ 8:30 pm ET with @DrJayyy__ @DavidACohen_MD discussing semaglutide for wei…
Obesity rates are increasing around the world, affecting 650 million people and counting. Advances in medicine like this newly released trial could be a “game-changer” for patients with the disease. Learn more in @NEJM: https://t.co/sBEgHsAXW4 #advancesinhealthcare #obesity https://t.co/ddWo0aTix1
RT @DrPess: It’s back! #EndoTwitter Journal Club Wed, April 7th @ 8:30 pm ET with @DrJayyy__ @DavidACohen_MD discussing semaglutide for wei…
RT @DavidACohen_MD: ATTENTION! The next #EndoTwitter Journal Club will be next Wed, April 7 @ 830 EDT. @DrJayyy__ & @DavidACohen_MD will…
RT @DrPess: It’s back! #EndoTwitter Journal Club Wed, April 7th @ 8:30 pm ET with @DrJayyy__ @DavidACohen_MD discussing semaglutide for wei…
RT @DrPess: It’s back! #EndoTwitter Journal Club Wed, April 7th @ 8:30 pm ET with @DrJayyy__ @DavidACohen_MD discussing semaglutide for wei…
It’s back! #EndoTwitter Journal Club Wed, April 7th @ 8:30 pm ET with @DrJayyy__ @DavidACohen_MD discussing semaglutide for weight loss. Save the date!
RT @DavidACohen_MD: ATTENTION! The next #EndoTwitter Journal Club will be next Wed, April 7 @ 830 EDT. @DrJayyy__ & @DavidACohen_MD will…
RT @DavidACohen_MD: ATTENTION! The next #EndoTwitter Journal Club will be next Wed, April 7 @ 830 EDT. @DrJayyy__ & @DavidACohen_MD will…
RT @DavidACohen_MD: ATTENTION! The next #EndoTwitter Journal Club will be next Wed, April 7 @ 830 EDT. @DrJayyy__ & @DavidACohen_MD will…
ATTENTION! The next #EndoTwitter Journal Club will be next Wed, April 7 @ 830 EDT. @DrJayyy__ & @DavidACohen_MD will be discussing the recent @NEJM article on weekly semaglutide for weight loss See you there! @EndoJournalClub @dclieb @ENDOUNO @DrPess https://t.co/tZ9vGFXT1K
2021/3/18 出版分 twitterでバズった論文 全分野 Once-Weekly Semaglutide in Adults with Overweight or Obesity https://t.co/V5xrFDdJPQ Tweets: 1910 痩せ薬としてのセマグルチドのRCT。
The paper link is here @NEJM https://t.co/02GVlXomcw
Here is the trial we will be discussing - just published in @NEJM https://t.co/tcaprD6O7D
#TwitteRx | “2.4 mg of semaglutide once weekly plus lifestyle intervention was associated with sustained, clinically relevant reduction in body weight.” https://t.co/oFaqD0auic
@DrMAlAteeq دراسة جديدة نشرت في مجلة NEJM اجريت على هذا الدواء لتخفيف الوزن اظهرت نتائج رائعة لمن يعانون زيادة وزن أو سمنة وقد تكون هي الخيار القادم كونها ابرة اسبوعية. https://t.co/Qe5LJa8MzT
RT @FIP_BPS: #GLP-1 receptor agonist #semaglutide cuts bodyweight by 20% in third of trial participants and is hailed a “game changer” for…
RT @FIP_BPS: #GLP-1 receptor agonist #semaglutide cuts bodyweight by 20% in third of trial participants and is hailed a “game changer” for…
#GLP-1 receptor agonist #semaglutide cuts bodyweight by 20% in third of trial participants and is hailed a “game changer” for #obesity by researchers @ucl, UK. https://t.co/udmg25zS0B Read the abstract here: https://t.co/f6iQRgV5TM #PharmaceuticalSciences https://t.co/Id14rSZeiv
@PodcastSinmas https://t.co/2JiI2Py9Ie
A study with or without a mechanism of action: https://t.co/5rvOGgGNIv https://t.co/kXXhkiZf7F The former one was published in The New England Journal of Medicine (NEJM), with an impact factor of 79.358, while the latter one was published at https://t.co/X6HUOniPOB. https://t.co/nLDqZsmQ80
A study without a mechanism of action (NEJM): Once-Weekly Semaglutide in Adults with Overweight or Obesity https://t.co/5rvOGgGNIv A study with a mechanism of action: Semaglutide-based therapy for TIIDM and obesity-associated metabolic deficits: https://t.co/kXXhkiZf7F https://t.co/DZaAyTtp8n
A study without a mechanism of action(NEJM): Once-Weekly Semaglutide in Adults with Overweight or Obesity https://t.co/5rvOGgGNIv A study with a mechanism of action: Semaglutide-based therapy for TIIDM and obesity-associated metabolic deficits: https://t.co/kXXhkiZf7F https://t.co/ivclZtsKhh
A study without a mechanism of action (NEJM): Once-Weekly Semaglutide in Adults with Overweight or Obesity https://t.co/5rvOGgGNIv A study with a mechanism of action: Semaglutide-based therapy for TIIDM and obesity-associated metabolic deficits: https://t.co/kXXhkiZf7F https://t.co/peUPbxehrm
A study without a mechanism of action (NEJM): Once-Weekly Semaglutide in Adults with Overweight or Obesity https://t.co/5rvOGgGNIv A study with a mechanism of action : Semaglutide-based therapy for TIIDM and obesity-associated metabolic deficits: https://t.co/kXXhkiZf7F
Once-Weekly Semaglutide in Adults with Overweight or Obesity https://t.co/vtPsJqBjZf
A viable fatbuster at last? "35% of people who took a new drug for treating #obesity lost more than one-fifth of their total body weight." That drug is semaglutide, given once weekly in a dose of 2.4mg. It may be a gamechanger. #obese #fat https://t.co/LQcoCdasxv
RT @ichiipsy: The New England Journal of Medicineによれば、約2,000人の肥満成人を対象とした研究によって、糖尿病の治療であるセマグルチドの週1回の使用と減量によって15％程度の体重減少が認められたらしい。プラセボ群に比べても大…
RT @ichiipsy: The New England Journal of Medicineによれば、約2,000人の肥満成人を対象とした研究によって、糖尿病の治療であるセマグルチドの週1回の使用と減量によって15％程度の体重減少が認められたらしい。プラセボ群に比べても大…
@ObesitySociety #clinicaltrials #PubMed Once-Weekly Semaglutide in Adults with Overweight or Obesity https://t.co/tCjifOZHNs
Once-Weekly Semaglutide in Adults with Overweight or Obesity - PubMed https://t.co/z2iO0uyXvZ これかな？
Trending on PubMed: Once-Weekly Semaglutide in Adults with Overweight or Obesity. https://t.co/9DukIGOJzn
Given 'we' seem to have had some part in medicalising this major step in treating obesity, why has it not been championed in our media every day? https://t.co/JeBR8KM0S8 https://t.co/ngDziEbgsI
RT @pinacol: 【RCT】糖尿病のないBMI30以上の成人に対する生活習慣への介入へのセマグルチドの追加は、プラセボの追加と比較して、体重を減少させ、5%以上の減量達成を増加させた。 #ペ読 https://t.co/7xjY4J10Tf
【RCT】糖尿病のないBMI30以上の成人に対する生活習慣への介入へのセマグルチドの追加は、プラセボの追加と比較して、体重を減少させ、5%以上の減量達成を増加させた。 #ペ読 https://t.co/7xjY4J10Tf
Promising findings for #obesity and hopefully another tool in the arsenal. Once-Weekly Semaglutide in Adults with Overweight or Obesity | NEJM https://t.co/dC5cPeCV83
The lit on weight loss drugs often features small studies of big effects. Surprisingly, a large 68 week study on a diabetes turned weight loss drug (N = 1,961 fat people) produced a mean weight loss of 15% of body weight (34lbs), consistent with what... https://t.co/3HH699WUkH
RT @ichiipsy: The New England Journal of Medicineによれば、約2,000人の肥満成人を対象とした研究によって、糖尿病の治療であるセマグルチドの週1回の使用と減量によって15％程度の体重減少が認められたらしい。プラセボ群に比べても大…
RT @ichiipsy: The New England Journal of Medicineによれば、約2,000人の肥満成人を対象とした研究によって、糖尿病の治療であるセマグルチドの週1回の使用と減量によって15％程度の体重減少が認められたらしい。プラセボ群に比べても大…
Nutshell #202: Patients with obesity who used semaglutide, an antidiabetic drug, and made lifestyle changes reduced weight by 14.9% during 68 weeks compared to 2.4% reduction in the placebo group with lifestyle changes. @NEJM https://t.co/FkQrK8S3wf
RT @ichiipsy: The New England Journal of Medicineによれば、約2,000人の肥満成人を対象とした研究によって、糖尿病の治療であるセマグルチドの週1回の使用と減量によって15％程度の体重減少が認められたらしい。プラセボ群に比べても大…
The New England Journal of Medicineによれば、約2,000人の肥満成人を対象とした研究によって、糖尿病の治療であるセマグルチドの週1回の使用と減量によって15％程度の体重減少が認められたらしい。プラセボ群に比べても大きな差が得られたようで、新しい減量治療になるかも https://t.co/TMMBUvIy1w
2021/2/10出版分 twitterでバズった論文 全分野 Once-Weekly Semaglutide in Adults with Overweight or Obesity https://t.co/lndcSiOeUi Tweets: 1179 日本ではリベルサスが商品名。 痩せ薬のホープとしてviralしそう。
Once weekly injection of the GLP-1 analogue, semaglutide, yields a 15.3 kg reduction in weight over 68 weeks vs a 2.6 kg loss in the placebo group (difference −12.7 kg; 95% CI, −13.7 to −11.7). Is this a practical intervention before elective surgery? https://t.co/J0VN2IDyj3
@TobyRichardsUWA @MrAhmedAhmed6 Careful, Toby, too much of this will put Ahmed out of a job... https://t.co/Bj0mR9SqDI
If diabetic medications can help those most in need, then perhaps the benefits outweigh the cons? But let's hope such people who become dependent on drugs have exhausted all other "healthier options" first. #obesity #diabetes #fatloss https://t.co/uUMjF6swBN
肥満（BMI30以上）にセマグルチドが効果的？ https://t.co/Z6Pc1NeuB4 did not have diabetes
RT @ProfBatterhamMD: A medical treatment for #obesity that leads to 10% weight loss in the majority and 20% weight loss in over a third of…
RT @ProfBatterhamMD: Honoured to be an author on @NEJM RCT paper. Lifestyle intervention+semaglutide 2.4mg vs lifestyle+placebo(P) in peop…
RT @ProfBatterhamMD: A medical treatment for #obesity that leads to 10% weight loss in the majority and 20% weight loss in over a third of…
RT @ProfBatterhamMD: A medical treatment for #obesity that leads to 10% weight loss in the majority and 20% weight loss in over a third of…
RT @ProfBatterhamMD: A medical treatment for #obesity that leads to 10% weight loss in the majority and 20% weight loss in over a third of…
CB
TL
KS